Expression of GIMAP7 in lung adenocarcinoma tissue and its clinical significance:a bioinformatics study
Objective To investigate the expression of GTPase of immunity-associated proteins(GIMAP)7 in lung adenocarcinoma(LUAD)tissue and its clinical significance.Methods The GIMAP7 transcriptome data and relevant clinical data of 539 LUAD patients were downloaded from the TCGA database.Patients were divided into high-expression(n=270)and low-expression(n=269)groups according to GIMAP7 expression level,and the overall survival(OS)and progressionfree interval(PFI)of patients in the two groups were compared.The surgical tissue samples of 20 patients who underwent surgical treatment and were pathologically diagnosed as LUAD in Taizhou First People's Hospital from June 2021 to June 2022 were collected for immunohistochemical staining to verify the expression level of GIMAP7.The study used TIMER and ESTIMATES score to analyze the relationship between GIMAP7 expression level and immune cell infiltration,and performed single sample gene set enrichment analysis(ssGSEA)to enrich the signaling pathway of GIMAP7 in LUAD tissue.Results TCGA database transcriptomic analysis showed low expression of GIMAP7 in LUAD tissue(P<0.05).The OS and PFI of GIMAP7 low expression group were both shorter than those of high expression group(P<0.001,0.013,respectively).The immunohi-stochemistry staining results of tissues from 20 patients with LUAD showed low expression of GIMAP7 in 85.00%(17/20)cases.The expression level of GIMAP7 was significantly correlated with the abundance of CD4+T cells,CD8+T cells,B cells,dendritic cells,macrophage,neutrophil,and ESTIMATES score(all P<0.001).SsGSEA analysis showed that GIMAP7 was mainly involved in adaptive immunity,leukocyte-mediated immune responses,lymphocyte-mediated immunity,nucleosome assembly,and other pathways.Conclusion GIMAP7 is significantly low expressed in LUAD,and the expression level of GIMAP7 is significantly correlated with immune cell infiltration.It is expected to be a novel biomarker for immunotherapy of LUAD.
Lung adenocarcinomaTumor microenvironmentTumor immunotherapyGTPase of immunity-associated proteins 7